Abstract

Amelanotic melanoma (AM) is a subtype of melanoma where the lesion demonstrates no pigmentation. This can lead to delays in referral with studies showing a higher mortality rate. To determine the characteristics of AM lesions, we conducted a retrospective analysis of patients with confirmed AM. Of the 16 patients, 68.75% were male and the mean age at diagnosis was 78 years. The most common location for AM was the head (37.5%) which also demonstrated a higher mitotic rate (10.67 mm2) compared to the average (7.31 mm2). More than half of the lesions (56%) had been present for more than 1 year. With a misdiagnosis rate of 87.5%, the likelihood of delays were evident. There was no unifying feature on clinical assessment, however conspicuous vessel findings were noted on 62.5% of lesions. We have demonstrated that AM continues to remain a missed diagnosis with the potential for a more lethal cancer to form.

INTRODUCTION

Amelanotic melanoma (AM) is a subtype of melanoma where the lesion phenotype demonstrates little to no pigmentation. It accounts for less than 2% of melanoma diagnosis, but is associated with a higher mortality rate [1, 2]. Amelanotic melanoma remains a diagnostic challenge as it mimics various benign and malignant conditions. A misdiagnosis rate of up to 89% has been reported [3]. It is often detected at later stages in disease progression, potentially secondary to delays in referral due to misdiagnosis with a consequently more lethal disease developing. Thomas et al. conducted an international population based study which highlighted several key characteristics regarding AM [4]. The study identified 8% of melanomas were histopathologically amelanotic (275 out of 3467). Amelanotic melanoma was identified to generally have a higher tumour stage at diagnosis in comparison to pigmented melanoma. Furthermore, AM had a greater hazard of death compared to pigmented melanoma, with a hazard ratio of 2.0. The study concluded that survival after diagnosis of AM was poorer than pigmented melanoma, due to a more advanced stage at diagnosis, likely due to difficulties and delays in diagnosis. There are few reports in the current literature regarding AM, which limits our understanding of its associated characteristics. Herein we present a case series of 16 patients with AM, reporting the clinical and histological features of the disease. The objective of this report is to educate and increase the awareness of AM by increasing the understanding of the clinical and histopathological characteristics associated with AM.

REPORT

In a 10-year period at a single centre in the Northwest of England, patients with a histological diagnosis of AM were enrolled and data collated retrospectively. Consent for research was obtained from each patient at biopsy.

Table 1 summarises demographics, clinical presentation and histological characteristics of the lesions. A total of 16 patients were diagnosed with AM. There were 11 men and 5 women with a mean age at diagnosis of 78 years (male mean age 77 years, female mean age 79 years). Amelanotic melanoma was most commonly seen to manifest in the head (37.5%), followed by the legs (25%), back (18.8%), arms (12.5%) and neck (6.25%). The average size of the lesion at diagnosis was 13.88 mm (minimum size 5 mm, maximum size 35 mm). The average Breslow thickness was 3.16 mm (minimum thickness 0.2 mm, maximum thickness 5.7 mm) and an average mitotic rate of 7.31 mm2 (minimum rate of 0 mm2, maximum rate of 23 mm2). Interestingly, the average Breslow thickness of lesions on the back (4.07 mm) was notably higher than the overall average. In contrast, the average mitotic rate was highest in lesions of the head (10.67 mm2) and leg (9 mm2). The most common histological subtype was nodular (62.5%), followed by superficial spreading (18.75%), lentigo maligna melanoma (6.25%), desmoplastic (6.25%) and balloon (6.25%). Desmoplastic and lentigo maligna melanoma subtypes both had a notably higher Breslow thickness than the average at 5.5 mm.

Table 1

Patient demographics and summary of AM features (SSM—superficial spreading melanoma; LMM—lentigo maligna melanoma; NMSC—non-melanoma skin cancer)

Patient no.Age at diagnosisSexSiteSize (mm)History of NMSCBreslow Thickness (mm)Mitotic Rate (mm2)Histological Subtype
177MaleBack10No3.05Nodular
280MaleLeg20No2.612SSM
388MaleHead20Yes5.56LMM
480FemaleLeg8No1.55SSM
572MaleArm5No1.77Nodular
692MaleHead12No5.723Nodular
780FemaleLeg8No2.68Nodular
884MaleBack173.71Nodular
973MaleBack15No5.52Desmoplastic
1087MaleHead9Yes5.416Nodular
1183MaleArm11No2.72Nodular
1280FemaleHead8No1.94Nodular
1333MaleNeck35No2.50Balloon
1475FemaleLeg10No3.811Nodular
1579MaleHead20No0.20SSM
1680FemaleHead14No2.315Nodular
Patient no.Age at diagnosisSexSiteSize (mm)History of NMSCBreslow Thickness (mm)Mitotic Rate (mm2)Histological Subtype
177MaleBack10No3.05Nodular
280MaleLeg20No2.612SSM
388MaleHead20Yes5.56LMM
480FemaleLeg8No1.55SSM
572MaleArm5No1.77Nodular
692MaleHead12No5.723Nodular
780FemaleLeg8No2.68Nodular
884MaleBack173.71Nodular
973MaleBack15No5.52Desmoplastic
1087MaleHead9Yes5.416Nodular
1183MaleArm11No2.72Nodular
1280FemaleHead8No1.94Nodular
1333MaleNeck35No2.50Balloon
1475FemaleLeg10No3.811Nodular
1579MaleHead20No0.20SSM
1680FemaleHead14No2.315Nodular
Table 1

Patient demographics and summary of AM features (SSM—superficial spreading melanoma; LMM—lentigo maligna melanoma; NMSC—non-melanoma skin cancer)

Patient no.Age at diagnosisSexSiteSize (mm)History of NMSCBreslow Thickness (mm)Mitotic Rate (mm2)Histological Subtype
177MaleBack10No3.05Nodular
280MaleLeg20No2.612SSM
388MaleHead20Yes5.56LMM
480FemaleLeg8No1.55SSM
572MaleArm5No1.77Nodular
692MaleHead12No5.723Nodular
780FemaleLeg8No2.68Nodular
884MaleBack173.71Nodular
973MaleBack15No5.52Desmoplastic
1087MaleHead9Yes5.416Nodular
1183MaleArm11No2.72Nodular
1280FemaleHead8No1.94Nodular
1333MaleNeck35No2.50Balloon
1475FemaleLeg10No3.811Nodular
1579MaleHead20No0.20SSM
1680FemaleHead14No2.315Nodular
Patient no.Age at diagnosisSexSiteSize (mm)History of NMSCBreslow Thickness (mm)Mitotic Rate (mm2)Histological Subtype
177MaleBack10No3.05Nodular
280MaleLeg20No2.612SSM
388MaleHead20Yes5.56LMM
480FemaleLeg8No1.55SSM
572MaleArm5No1.77Nodular
692MaleHead12No5.723Nodular
780FemaleLeg8No2.68Nodular
884MaleBack173.71Nodular
973MaleBack15No5.52Desmoplastic
1087MaleHead9Yes5.416Nodular
1183MaleArm11No2.72Nodular
1280FemaleHead8No1.94Nodular
1333MaleNeck35No2.50Balloon
1475FemaleLeg10No3.811Nodular
1579MaleHead20No0.20SSM
1680FemaleHead14No2.315Nodular

Table 2 summarises the clinical findings and dermoscopic descriptions during clinical examination. In our series, the clinical misdiagnosis rate was 87.5% with squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) the most common misdiagnoses, accounting for 9 of 16 cases. Onset of lesions were an almost even split, with 56% of lesions reported as longstanding (>12 months) and 44% recent (<12 months). Lesions were noted as non-ulcerated (75%), erythematous (50%) or yellow plaque (12.5%), however there was variation amongst the lesions with no unifying common feature. Dermoscopic findings were variable, but conspicuous vessels were noted in 62.5% of lesions. The most common vessel patterns were linear and irregular vessels, both identified in 18.75% of cases with 12.5% of cases showing arborising vessels.

Table 2

Summary of AM clinical and dermoscopic findings (BCC—basal cell carcinoma; SCC—squamous cell carcinoma; AM—amelanotic melanoma)

Patient No.Clinical DescriptionDermoscopic DescriptionUlceration PresentClinical DiagnosisDuration
1Pearly erythematous noduleWhite scar-like centre and enlarged linear tortuous vessels, asymmetric at the peripheryNoBCCLongstanding
2Erythematous firm noduleCrystalline structures, irregular vessels with background inflammationNoAMLongstanding
3NodularIrregular vessels, perifollicular rosettesNoSCCLongstanding
4Asymptomatic, ulcerated warty noduleNoSCCRecent
5Pink, nodule with surrounding actinic damageNoBCCLongstanding
6Bleeding, nodular non-specificAbnormal enlarged linear vesselsYesSCCLongstanding
7Bleeding non-healing ulcerArborising vesselsYesBCCRecent
8Erythematous dome shaped noduleCoiled vesselsNoAMRecent
9Erythematous non-tender plaque with dermal involvementArborising vesselsNoBCCRecent
10Haemorrhagic crust, non-healingNoSCCLongstanding
11Bleeding red noduleIrregular vesselsYesSCCRecent
12Asymptomatic, erythematous noduleWell circumscribed enlarged symmetric vessels, no pigmentNoIrritated compound melanocytic naevusRecent
13Yellow plaqueYellow amorphousNoXanthelasmaLongstanding
14NodularNoDermatofibromaLongstanding
15Erythematous plaque with enlarged pores, attached to previous scar from junctional naevusNoGranuloma facialeLongstanding
16Rapidly enlarging yellow nodule, occaisionally bleedsLinear vesselsYesRecent
Patient No.Clinical DescriptionDermoscopic DescriptionUlceration PresentClinical DiagnosisDuration
1Pearly erythematous noduleWhite scar-like centre and enlarged linear tortuous vessels, asymmetric at the peripheryNoBCCLongstanding
2Erythematous firm noduleCrystalline structures, irregular vessels with background inflammationNoAMLongstanding
3NodularIrregular vessels, perifollicular rosettesNoSCCLongstanding
4Asymptomatic, ulcerated warty noduleNoSCCRecent
5Pink, nodule with surrounding actinic damageNoBCCLongstanding
6Bleeding, nodular non-specificAbnormal enlarged linear vesselsYesSCCLongstanding
7Bleeding non-healing ulcerArborising vesselsYesBCCRecent
8Erythematous dome shaped noduleCoiled vesselsNoAMRecent
9Erythematous non-tender plaque with dermal involvementArborising vesselsNoBCCRecent
10Haemorrhagic crust, non-healingNoSCCLongstanding
11Bleeding red noduleIrregular vesselsYesSCCRecent
12Asymptomatic, erythematous noduleWell circumscribed enlarged symmetric vessels, no pigmentNoIrritated compound melanocytic naevusRecent
13Yellow plaqueYellow amorphousNoXanthelasmaLongstanding
14NodularNoDermatofibromaLongstanding
15Erythematous plaque with enlarged pores, attached to previous scar from junctional naevusNoGranuloma facialeLongstanding
16Rapidly enlarging yellow nodule, occaisionally bleedsLinear vesselsYesRecent
Table 2

Summary of AM clinical and dermoscopic findings (BCC—basal cell carcinoma; SCC—squamous cell carcinoma; AM—amelanotic melanoma)

Patient No.Clinical DescriptionDermoscopic DescriptionUlceration PresentClinical DiagnosisDuration
1Pearly erythematous noduleWhite scar-like centre and enlarged linear tortuous vessels, asymmetric at the peripheryNoBCCLongstanding
2Erythematous firm noduleCrystalline structures, irregular vessels with background inflammationNoAMLongstanding
3NodularIrregular vessels, perifollicular rosettesNoSCCLongstanding
4Asymptomatic, ulcerated warty noduleNoSCCRecent
5Pink, nodule with surrounding actinic damageNoBCCLongstanding
6Bleeding, nodular non-specificAbnormal enlarged linear vesselsYesSCCLongstanding
7Bleeding non-healing ulcerArborising vesselsYesBCCRecent
8Erythematous dome shaped noduleCoiled vesselsNoAMRecent
9Erythematous non-tender plaque with dermal involvementArborising vesselsNoBCCRecent
10Haemorrhagic crust, non-healingNoSCCLongstanding
11Bleeding red noduleIrregular vesselsYesSCCRecent
12Asymptomatic, erythematous noduleWell circumscribed enlarged symmetric vessels, no pigmentNoIrritated compound melanocytic naevusRecent
13Yellow plaqueYellow amorphousNoXanthelasmaLongstanding
14NodularNoDermatofibromaLongstanding
15Erythematous plaque with enlarged pores, attached to previous scar from junctional naevusNoGranuloma facialeLongstanding
16Rapidly enlarging yellow nodule, occaisionally bleedsLinear vesselsYesRecent
Patient No.Clinical DescriptionDermoscopic DescriptionUlceration PresentClinical DiagnosisDuration
1Pearly erythematous noduleWhite scar-like centre and enlarged linear tortuous vessels, asymmetric at the peripheryNoBCCLongstanding
2Erythematous firm noduleCrystalline structures, irregular vessels with background inflammationNoAMLongstanding
3NodularIrregular vessels, perifollicular rosettesNoSCCLongstanding
4Asymptomatic, ulcerated warty noduleNoSCCRecent
5Pink, nodule with surrounding actinic damageNoBCCLongstanding
6Bleeding, nodular non-specificAbnormal enlarged linear vesselsYesSCCLongstanding
7Bleeding non-healing ulcerArborising vesselsYesBCCRecent
8Erythematous dome shaped noduleCoiled vesselsNoAMRecent
9Erythematous non-tender plaque with dermal involvementArborising vesselsNoBCCRecent
10Haemorrhagic crust, non-healingNoSCCLongstanding
11Bleeding red noduleIrregular vesselsYesSCCRecent
12Asymptomatic, erythematous noduleWell circumscribed enlarged symmetric vessels, no pigmentNoIrritated compound melanocytic naevusRecent
13Yellow plaqueYellow amorphousNoXanthelasmaLongstanding
14NodularNoDermatofibromaLongstanding
15Erythematous plaque with enlarged pores, attached to previous scar from junctional naevusNoGranuloma facialeLongstanding
16Rapidly enlarging yellow nodule, occaisionally bleedsLinear vesselsYesRecent

DISCUSSION

Our case series demonstrates that almost all patients with AM were elderly (>70 years-old). This is in keeping with the general statistics of melanoma incidence which increases with age, with the highest rates in the 85–89 age group for both males and females [5]. Furthermore, our cohort were predominantly male, which also follows the general trend in melanoma incidence where rates are higher in males in the older age groups [5].

The most common site in our series was an exposed area which was the head. This is contrary to the current statistics of melanoma, where the most common location is the trunk [5]. According to the literature, melanomas which develop on the trunk occur more often in the fifth to sixth decades of life, whereas melanomas that develop in high ultra violet (UV) exposed body regions, like the head and neck, occur more commonly in the eighth decade [3]. Due to the older age and mainly exposed sites of involvement, it is most likely that chronic UV exposure rather than intermittent is leading to the development of AM.

The overall Breslow thickness was found to be high, which is in accordance to previous reports and likely to be related to a delay in diagnosis. Furthermore, a higher mitotic rate was noted in AM on the head, which may suggest a more aggressive nature of AM in exposed areas. The most common clinical misdiagnosis of AM was BCC and SCC and this is in agreement with previous reports [6].

Dermoscopic characteristics predominantly consisted of vascular abnormalities. Dermoscopy is a vital component of detecting abnormal features which can suggest AM. Vessel analysis is recommended for lesions which lack pigmentation to identify suspicious lesions, with the 5 + 2 list used to guide vessel analysis [7]. Vascular patterns which raise the suspicion of melanoma include irregular dot, linear irregular, arborising and polymorphic vessels. These patterns have been highlighted in a larger cohort study by Paolino et al. where there was high prevalence of linear looped vessels (58.8%), linear irregular vessels (50.0%) and arborising vessels (47.2%) [8]. Considering 62.5% of the AM lesions in our series had vessel features in accordance with the aforementioned report, we would recommend that any lesion suspicious for AM should have dermoscopy assessment with specific focus on identifying the aforementioned vessel features [9].

We recognise the limitations of our study, principally the small sample size and no follow up. Furthermore, dermoscopic data were often incomplete and lacking detail, making the clinical assessment analysis more difficult. Regardless, we have demonstrated that AM can have a significant misdiagnosis rate with the possibility for a more aggressive cancer to form, potentially leading to unfavourable patient outcomes. We have also demonstrated key features of suspicious lesions which require assessment, notably abnormal vessels. Practitioners in primary and secondary care should be aware of and vigilant in identifying AM and arranging further appropriate investigation.

ACKNOWLEDGEMENTS

None.

AUTHOR CONTRIBUTIONS

Aroon Sohail (Investigation, writing—original draft, corresponding author) and Svetlana Kavaklieva (Supervision, writing—review and editing).

CONFLICT OF INTEREST STATEMENT

Authors declare that they have no competing interests.

FUNDING

The authors received no funding for this work.

ETHICAL APPROVAL

Ethical Approval was provided/waived by the authors institution.

CONSENT

Informed consent was obtained from each patient at the time of biopsy.

GUARANTOR

Dr Aroon Sohail.

RESEARCH REGISTRATION

None.

PROVENANCE AND PEER REVIEW

Not commissioned, externally peer reviewed.

REFERENCES

1.

Moreau
 
JF
,
Weissfeld
 
JL
,
Ferris
 
LK
.
Characteristics and survival of patients with invasive amelanotic melanoma in the USA
.
Melanoma Res
 
2013
 
[cited 2023 Jan 16]
;
23
:
408
13
.
Available from:
 https://journals.lww.com/melanomaresearch/Fulltext/2013/10000/Characteristics_and_survival_of_patients_with.10.aspx.

2.

Detrixhe
 
A
,
Libon
 
F
,
Mansuy
 
M
,
Nikkels-Tassoudji
 
N
,
Rorive
 
A
,
Arrese
 
JE
. et al.  
Melanoma masquerading as nonmelanocytic lesions
.
Melanoma Res
 
2016
 
[cited 2023 Jan 16]
;
26
:
631
4
.
Available from:
 https://journals.lww.com/melanomaresearch/Fulltext/2016/12000/Melanoma_masquerading_as_nonmelanocytic_lesions.12.aspx.

3.

Gong
 
HZ
,
Zheng
 
HY
,
Li
 
J
.
Amelanotic melanoma
.
Melanoma Res
 
2019
 
[cited 2023 Jan 16]
;
29
:
221
30
.
Available from:
 https://journals.lww.com/melanomaresearch/Fulltext/2019/06000/Amelanotic_melanoma.1.aspx.

4.

Thomas
 
NE
,
Kricker
 
A
,
Waxweiler
 
WT
,
Dillon
 
PM
,
Busam
 
KJ
,
From
 
L
. et al.  
Comparison of Clinicopathologic features and survival of Histopathologically Amelanotic and pigmented melanomas: a population-based study NIH public access
.
JAMA Dermatol
 
2014
;
150
:
1306
14
.

6.

McClain
 
SE
,
Mayo
 
KB
,
Shada
 
AL
,
Smolkin
 
ME
,
Patterson
 
JW
,
Slingluff
 
CL
.
Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences
.
Int J Dermatol
 
2012
 
[cited 2023 Jan 16]
;
51
:
420
6
 
Available from: /pmc/articles/PMC4465919/
.

7.

Kreusch
 
J
,
Koch
 
F
.
Incident light microscopic characterization of vascular patterns in skin tumors
.
Hautarzt
 
1996
 
[cited 2023 Jan 16]
;
47
:
264
72
.
Available from:
 https://pubmed.ncbi.nlm.nih.gov/8655309/.

8.

Paolino
 
G
,
Bearzi
 
P
,
Pampena
 
R
,
Longo
 
C
,
Frascione
 
P
,
Rizzo
 
N
. et al.  
Clinicopathological and dermoscopic features of amelanotic and hypomelanotic melanoma: a retrospective multicentric study
.
Int J Dermatol
 
2020
 
[cited 2024 Jan 20]
;
59
:
1371
80
.
Available from:
 https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.15064.

9.

Dawood
 
S
,
Altayeb
 
A
,
Atwan
 
A
,
Mills
 
C
.
Dermoscopic features of amelanotic and hypomelanotic melanomas: a review of 49 cases
.
Dermatol Pract Concept
 
2022
 
[cited 2023 Jan 28]
;
12
:
e2022060
 
Available from: /pmc/articles/PMC9116512/
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.